ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Hendrik Jan Ankersmit
Ernst Wolner
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ankersmit, H. J.
Right arrow Articles by Wolner, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ankersmit, H. J.
Right arrow Articles by Wolner, E.
Related Collections
Right arrow Mechanical Circulatory Assistance

Ann Thorac Surg 2006;82:893-894
© 2006 The Society of Thoracic Surgeons

Original article: Cardiovascular

Invited commentary

Hendrik Jan Ankersmit, MD, Bernhard Moser, MD, Ernst Wolner, MD

Department of Cardiothoracic Surgery, General Hospital Vienna, Meduniwien, Währinger Gürtel 18-20, Vienna, A-1090 Austria

(Email: hjankersmit@hotmail.com).

The first 20% of the full text of this article appears below.

Pulsatile and axial ventricular assist devices (VADs) have found acceptance as life sustaining pumps in regard to the "bridge to transplantation concept" or "destination therapy" in patients with terminal heart failure. Immunologic consequences have been described regarding increased susceptibility to acquire infections [1] and B-cell hyper-reactivity [2, 3], as determined by HLA antibody production. This process was termed sensitization, and the latter finding was described in patients who received pulsatile VAD systems. Recent reports have linked this laboratory finding to increased rejection rates and worsened transplant outcome in this patient cohort. Intravenous immunoglobulin (IVIG) was suggested to be beneficial . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2006 by The Society of Thoracic Surgeons.